HeartMate 3 LVAD is a crucial solution for patients with advanced heart failure who do not respond to medical treatments2
The HeartMate 3™ LVAD has significantly advanced the field of LVAD therapy, setting the standard with innovation and exceptional clinical outcomes.1 Its Full MagLev™ Flow Technology ensures gentle blood handling, minimizing complications and reducing hemocompatibility-related adverse events (HRAEs).**,1
HeartMate 3 LVAD, a proven long-term, life-extending therapy1 for advanced heart failure patients.
Median survival
exceeding 5 years1
58.4% survival at 5 years1
Reduction in HRAE-related mortality1
** Key adverse events include pump thrombosis, stroke and gastrointestinal (GI) bleeding.
For more information about the HeartMate 3 LVAD, see the clinical evidence or ask a clinical specialist.
Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure: Journal of Cardiac Failure
Learn why heart failure guidelines recommend it's time to consider an LVAD for your inotrope-dependent patients.
Inotropes can help heart failure symptoms in the short term but are not a life-saving therapy2
For patients with advanced heart failure, the likelihood of long-term survival without an LVAD or a heart transplant is extremely low.2
Due to poor outcomes associated with long-term inotrope use when a transplant or LVAD is an option, the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Failure Society of America (HFSA) have issued a 3 Harm recommendation. This indicates that the risks of long-term inotrope therapy far outweigh the benefits if a transplant or LVAD if available.3
Patients on long-term inotrope support have a median survival of under a year3
Without an LVAD or transplant, advanced heart failure patients would not be expected to survive beyond 9 months.1,2,*
{listNumber}
Please re-enter your address, or select Geo-Target, to view nearby donation centers
Clinics are listed in order of geographic proximity from the information entered in the locator. Abbott does not endorse any of the clinics on this locator, but merely provides them as a courtesy to patients. Nor does Abbott represent that this is a full list of clinics in a particular location. Though Abbott attempts to regularly update the locator, the locator may not have the latest information regarding the clinic or provider, or availability of product. The clinics are included in the locator because they are certified as a HeartMate LVAD implanting center, have ordered at least one HeartMate LVAD in the last 12 months, and have all HeartMate LVAD device-related equipment required for patient management. The number of orders has been validated; the number of implants has not been validated. This locator includes US clinics only. No clinics or healthcare professionals (HCPs) have paid or received a fee to be listed, but some HCPs within the clinics on this locator may purchase products from Abbott, provide consulting services to Abbott, and/or may have a financial relationship with Abbott. The locator is not meant to be an endorsement for any particular clinic, nor does it represent the qualifications of the HCPs at the clinic. Note that Abbott is a medical device manufacturer and cannot provide medical advice.
For more information about this clinic locator please see our policy. Any information you provide is covered by Abbott’s Privacy Policy
Patient Education for Heart Failure
A resource to help patients learn more about heart failure and understand how LVAD therapy can save their life.
*Patients on inotropes who did not receive a transplant or left ventricular assist device.
**Key adverse events include pump thrombosis, stroke and gastrointestinal (GI) bleeding.
References
- Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28(5):e1-e167
- Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8(5):880-886
- Sami F, Acharya P, Noonan G, et al. Palliative inotropes in advanced heart failure: comparing outcomes between milrinone and dobutamine. J Card Fail. 2022;28(12):1683-1691
MAT-2508546 v1.0
Stay Connected